NCT06910098View on ClinicalTrials.gov

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

NACompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

August 31, 2024

Conditions
LDL - Low Density Lipoprotein Receptor DisorderRosuvastatin
Interventions
DRUG

Rosuvastatin

a dose of 5mg were given and were compared for the cpk, ast and ldl levels

DRUG

Rosuvastatin

a dose of 10 mg were given and were compared for the cpk, ast and ldl levels

DRUG

Rosuvastatin

a dose of 20 mg were given and were compared for the cpk, ast and ldl levels

Trial Locations (1)

54600

Central Park Teaching Hospital, Lahore

All Listed Sponsors
lead

Central Park Medical College

OTHER

NCT06910098 - Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels | Biotech Hunter | Biotech Hunter